Press Release Summary:
- Enables remote data capture of symptomatic events and multi-parameter biometrics for complex care and symptoms directly associated with COVID-19
- Offers multi-parameter remote patient monitoring and algorithmic reporting of minute-level vital signs, physiological biometrics and symptomatic events
- Features remote data capture and reporting of patient's symptomatic coughing, sneezing and vomiting frequency
Original Press Release:
BioIntelliSense Expands Its Medical-Grade Data Services for Remote Care with First-of-its-Kind Symptomatic Events and Biometric Monitoring
FDA-cleared BioSticker™ medical device enables remote data capture of symptomatic events and multi-parameter biometrics for complex care and symptoms directly associated with COVID-19
DENVER, March 10, 2020 /PRNewswire/ -- BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced the addition of symptomatic events and multi-parameter biometric monitoring to its Data-as-a-Service (DaaS) platform. BioIntelliSense offers a medical-grade data service enabling early detection and longitudinal management of a patient's condition at home through actionable clinical insights at a fraction of the cost of traditional Remote Patient Monitoring (RPM).
BioIntelliSense's BioSticker™ medical device and data services now enable effortless remote data capture and reporting of a patient's symptomatic coughing, sneezing and vomiting frequency.
"This represents a major breakthrough in clinical medicine. Objective measurement and trending of a patient's symptomatic events, in addition to vital signs of skin temperature, respiratory rate and heart rate at rest, enable opportunities for earlier, proactive clinical intervention," said James Mault, MD, CEO of BioIntelliSense.
A distinctive dimension of the medical-grade BioIntelliSense data service is that it offers multi-parameter remote patient monitoring and algorithmic reporting of minute-level vital signs, physiological biometrics and symptomatic events continuously for up to 30 days without charging via the BioSticker, a discreet single-use wearable device.
The BioIntelliSense DaaS platform can be applied to a wide range of clinical use cases, such as perioperative orthopedic joint replacement, oncology and infectious disease monitoring, including the primary symptoms associated with COVID – 19, as described by the Centers for Disease Control and Prevention (CDC.gov Coronavirus Symptoms).
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures minute-to-minute vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The FDA-cleared BioSticker™ device makes remote monitoring and early detection simple. Through the platform's advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical grade care in the home.
For more information on how BioIntelliSense is redefining remote patient monitoring through medical-grade and cost-effective data services, please contact us at firstname.lastname@example.org or visit our website at BioIntelliSense.com.